Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2023-11-29 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于筹划重大事项的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the progress of planning a major matter, specifically a major asset restructuring and mixed ownership reform. It mentions that no formal agreement has been signed yet and that the company will continue to disclose information as required by laws and regulations. The document is relatively short (1106 characters) and serves as a progress update on a significant transaction rather than the transaction completion or detailed financial report. It does not contain financial statements or detailed analysis but is an ongoing disclosure about a major corporate event. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including major asset restructurings and ownership reforms.
2023-11-29 Chinese
关于为控股子公司提供担保实施情况的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the implementation of guarantees provided for its controlling subsidiaries. It lists multiple guarantee contracts with banks and financial institutions, specifying amounts, contract parties, guarantee scope, and periods. The document is an official disclosure about the company's guarantee activities to support subsidiaries' financing needs. It does not contain financial statements, audit opinions, or management discussions typical of annual or interim reports. It is not a call transcript, earnings release, or merger announcement. The content is regulatory in nature, providing detailed information about guarantees and related contracts, which fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and compliance disclosure that does not fit other specific categories.
2023-11-29 Chinese
关于参加深圳辖区上市公司2023年投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (606 characters) about the company's participation in an investor online reception day event. It mentions interaction with investors regarding company performance, governance, strategy, and sustainability, but does not contain any financial statements, detailed financial data, or report content. It is an announcement of an event rather than a report or transcript. The document is not a transcript of a call, nor a report or presentation. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about investor relations activities and does not fit other specific categories.
2023-11-10 Chinese
关于免去相关高级管理人员的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Shenzhen Haiwang Bioengineering Co., Ltd. about the removal of a senior management member (Vice President Bao Bingyong) due to internal work adjustments. It includes details about the board meeting where the decision was made, the independent directors' opinions, and mentions the repurchase and cancellation of shares related to the executive's equity incentive. The content focuses on management changes and related share transactions by a senior executive. There is no financial data, earnings information, or report publication mentioned. This fits the category of Board/Management Information (MANG) because it announces changes in senior management positions.
2023-10-29 Chinese
独立董事关于第九届董事局第九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the removal of a senior management member, specifically the vice president. It references compliance with company law, stock exchange listing rules, and company articles of association. The content focuses on board/management changes rather than financial results, audit, or other report types. The document length is short and it is clearly about management changes, not a full report or announcement of a report. Therefore, it fits best under Board/Management Information (MANG).
2023-10-29 Chinese
监事会决议公告
Report Publication Announcement Classification · 95% confidence The document is a formal announcement from the Supervisory Board of Shenzhen Haiwang Bioengineering Co., Ltd. regarding the approval of the company's 2023 third quarter report. It states that the Supervisory Board has reviewed and approved the Q3 report, confirming its compliance with laws and regulations and its accuracy. However, the document itself does not contain the actual financial data or the full report; instead, it references that the full 2023 third quarter report is published elsewhere (in newspapers and on a financial information website). The document is short (663 characters) and serves as a notice of the approval and publication of the interim report rather than the report itself. According to the "Menu vs Meal" rule, such announcements are classified as Report Publication Announcements (RPA).
2023-10-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.